Lonafarnib
- Generic Name
- Lonafarnib
- Brand Names
- Zokinvy
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31Br2ClN4O2
- CAS Number
- 193275-84-2
- Unique Ingredient Identifier
- IOW153004F
- Background
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, a...
- Indication
Lonafarnib is a farnesyltransferase inhibitor indicated in patients aged 12 months and older with a body surface area of at least 0.39 m to reduce the risk of mortality associated with Hutchinson-Gilford progeria syndrome (HGPS). It is also indicated in this same population for the treatment of processing-deficient progeroid laminopathies that either involve...
- Associated Conditions
- Death, Hutchinson-Gilford Progeria Syndrome, Processing-deficient Progeroid Laminopathies
- Associated Therapies
- -
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT00879034
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
Lonafarnib in Metastatic Breast Cancer
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- George Sledge
- Target Recruit Count
- 29
- Registration Number
- NCT00773474
- Locations
- 🇺🇸
Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States
🇺🇸Arnett Cancer Care, Lafayette, Indiana, United States
🇺🇸Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Monica E. Kleinman
- Target Recruit Count
- 29
- Registration Number
- NCT00425607
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Emory University
- Target Recruit Count
- 38
- Registration Number
- NCT00288444
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- AGO Study Group
- Target Recruit Count
- 105
- Registration Number
- NCT00281515
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde, Berlin, Germany
🇩🇪Ev. Krankenhaus, Frauenklinik, Düsseldorf, Germany
🇩🇪Klinikum Bremen Mitte, Frauenklinik, Bremen, Germany
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
- Conditions
- Interventions
- First Posted Date
- 2005-04-29
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00109538
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
- Conditions
- Interventions
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00102648
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00003956
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
- Conditions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2015-02-10
- Target Recruit Count
- 30
- Registration Number
- NCT00083096
- Locations
- 🇫🇷
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇫🇷Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
- First Posted Date
- 2004-04-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00081510
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.